Regeneron drug halves muscle loss with Novo's semaglutide in trial
An experimental weight-loss drug developed by Regeneron (REGN), when combined with Novo Nordisk's (NOVO_B) semaglutide, reduced muscle mass loss by 50% compared to semaglutide alone in a study of obese patients, according to trial data.